瑞舒伐他汀对高血压病合并2型糖尿病患者的降脂作用及对高敏C反应蛋白水平的影响

目的评估瑞舒伐他汀在高血压病合并2型糖尿病患者中对高敏C反应蛋白(hs-CRP)和血脂水平的疗效。方法 32例高血压合并2型糖尿病患者随机分成两组,常规组使用常规降压药物和控制血糖药物,瑞舒伐他汀组在降压药物和控制血糖药物基础上使用瑞舒伐他汀10 mg/d治疗4周。在治疗前后抽取静脉血送检,比较两组hs-CRP、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)和总胆固醇(TC)水平在治疗前后的变化,并监测不良反应。结果治疗4周后,对照组hs-CRP、LDL-C、TC和TG,HDL-C无明显变化,瑞舒伐他汀组能hs-CRP、LDL-C、TC和TG显著降低,HDL-C升高,与对照组相比,差异有显著统计学意义(P<0.01)。结论使用瑞舒伐他汀可以有效降低高血压病合并2型糖尿病患者的hs-CRP和血脂水平。

Effect of rosuvastatin on high-sensitivity C-reactive protein and lipid profile in patients with hypertension associated with type 2 diabetes mellitus

Objective To evaluate the effect of rosuvastatin on blood levels of high-sensitivity C-reactive protein（hs-CRP） and lipids in treatment of patients with hypertension associated with type 2 diabetes mellitus（T2DM）.Methods A total of 32 patients with hypertension associated with type 2 diabetes mellitus were allocated into two groups.Patients in control group were administered with routine antihypertensive and hypoglycemic drugs and those in trial group were additionally administered with rosuvastatin（10mg/d） for 4 weeks.The parameters for study were blood levels of hs-CRP and lipids including LDL-C,HDL-C,TG and TC.Results The changes in parameters after treatment clearly demonstrated that rosuvastatin could significantly lower hs-CRP level,reduce LDL-C level,elevate HDL-C level along with reducing levels of TC and TG in comparison to those of control group（P〈0.01）.Conclusion This study throws light on the fact that rosuvastatin should be preferable in treatment of patients with hypertension associated with T2DM,and it can be administrated for lowering hs-CRP level and elevation of HDL-C level or reducing TG level.